SCHEMBL6433064

SCHEMBL6433064

CC(C)(C)OC(=O)CCNS(=O)(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.38
PLAU P00749 2/20 0.37
F2 P00734 5/20 0.36
TMPRSS6 Q8IU80 4/20 0.36
TBXAS1 P24557 2/20 0.36
TBXA2R P21731 1/20 0.36
ALDH1A1 P00352 3/20 0.36
PRKD3 O94806 1/20 0.34
PRKCG P05129 1/20 0.34
PRKCB P05771 1/20 0.34
PRKCA P17252 1/20 0.34
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34
PRKCH P24723 1/20 0.34
PRKCI P41743 1/20 0.34
PRKCE Q02156 1/20 0.34
PRKCQ Q04759 1/20 0.34
PRKCZ Q05513 1/20 0.34
PRKCD Q05655 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6965041 0.91 F2 (0.35) PLAUF2TMPRSS6ALDH1A1ACACB
Hydrochloric Acid SCHEMBL6432755 0.90 F2 (0.35) PLAUF2TMPRSS6ALDH1A1ACACB
Trifluoroacetic Acid SCHEMBL7374048 0.83 PLAU (0.45) PLAUF2TMPRSS6ALDH1A1
SCHEMBL6433416 0.83 PLAU (0.32) PLAUF2
SCHEMBL6434466 0.83 NR1D1 (0.35) PLAU
Hydrochloric Acid SCHEMBL6433670 0.83 PLAU (0.51) PLAUF2CYP1A2CYP3A4CYP2D6
SCHEMBL7050063 0.82 PLAU (0.38) PLAUALDH1A1CYP3A4MEN1KMT2A
SCHEMBL6433843 0.82 DGAT2 (0.41) CYP3A4KMT2A
SCHEMBL6434837 0.81 PLAU (0.37) PLAUALDH1A1ACACB
SCHEMBL7367638 0.81 S1PR1 (0.40) S1PR1PLAUF2TMPRSS6TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 S1PR1 2770/4885PLAU 119/4885F2 350/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 S1PR1 2770/4885PLAU 119/4885F2 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.